- Home
- Publications
- Publication Search
- Publication Details
Title
Development and safety of PI3K inhibitors in cancer
Authors
Keywords
-
Journal
ARCHIVES OF TOXICOLOGY
Volume 97, Issue 3, Pages 635-650
Publisher
Springer Science and Business Media LLC
Online
2023-02-11
DOI
10.1007/s00204-023-03440-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer
- (2022) Felipe Batalini et al. CLINICAL CANCER RESEARCH
- A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
- (2022) Atish D. Choudhury et al. CLINICAL CANCER RESEARCH
- Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
- (2022) Simon Eschweiler et al. NATURE
- Ropivacaine inhibits wound healing by suppressing the proliferation and migration of keratinocytes via the PI3K/AKT/mTOR Pathway
- (2022) Xiaoyang Wu et al. BMC Anesthesiology
- Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach
- (2022) Lindsey E. Roeker et al. CLINICAL CANCER RESEARCH
- Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer
- (2021) Priyanka Sharma et al. CLINICAL CANCER RESEARCH
- Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma
- (2021) Nathan H. Fowler et al. JOURNAL OF CLINICAL ONCOLOGY
- Copanlisib for the Treatment of Malignant Lymphoma: Clinical Experience and Future Perspectives
- (2021) Javier Munoz et al. Targeted Oncology
- Inhibition of PI3K Isoform p110γ Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity
- (2021) Kelvin Anderson et al. Cancers
- Synergistic efficacy of dual PI3K-d/g inhibitor Duvelisib with Bcl2 inhibitor Venetoclax in Richter's Syndrome PDX models
- (2021) Andrea Iannello et al. BLOOD
- Umbralisib: First Approval
- (2021) Sohita Dhillon et al. DRUGS
- PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
- (2021) Rosalin Mishra et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
- (2021) Hope S Rugo et al. LANCET ONCOLOGY
- Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2021) Matthew J Matasar et al. LANCET ONCOLOGY
- Copanlisib safe and active in combination
- (2021) David Killock Nature Reviews Clinical Oncology
- The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
- (2021) Lisa Rohrbacher et al. Frontiers in Immunology
- Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia
- (2021) Cécile Tomowiak et al. Blood Advances
- The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
- (2021) Christiane Braun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
- (2021) Debashis Sarker et al. CLINICAL CANCER RESEARCH
- Development of PI3K inhibitors: advances in clinical trials and new strategies (Review)
- (2021) Dandan Meng et al. PHARMACOLOGICAL RESEARCH
- Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
- (2021) Ninghui Mao et al. Nature Communications
- Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
- (2021) Matthew S. Davids et al. Blood Advances
- Dominant Role of PI3K p110α over p110β in Insulin and β-Adrenergic Receptor Signalling
- (2021) Biqin Zhang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype
- (2021) Ralitsa R. Madsen et al. PLoS Genetics
- Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features
- (2020) Miriam Marqués et al. CANCER RESEARCH
- Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
- (2020) Georg Lenz et al. LEUKEMIA
- Time Course and Management of Key Adverse Events During the Randomized Phase 3 SOLAR-1 Study of PI3K Inhibitor Alpelisib Plus Fulvestrant in Patients With HR-Positive Advanced Breast Cancer
- (2020) H.S. Rugo et al. ANNALS OF ONCOLOGY
- Inhibition of Phosphatidylinositol 3-Kinase γ by IPI-549 Attenuates Abdominal Aortic Aneurysm Formation in Mice
- (2020) Rui Liu et al. EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY
- Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment
- (2020) Min Jiang et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- A phase 2 trial of buparlisib in patients with platinum‐resistant metastatic urothelial carcinoma
- (2020) Victor McPherson et al. CANCER
- p110δ PI3K as a therapeutic target of solid tumours
- (2020) Lydia Xenou et al. CLINICAL SCIENCE
- Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
- (2020) Mark Rosenthal et al. ESMO Open
- The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells
- (2020) Kamira Maharaj et al. Blood Advances
- A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients
- (2020) Matthew S. Davids et al. LEUKEMIA
- Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial
- (2020) H.-Y. Yhim et al. ANNALS OF ONCOLOGY
- Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
- (2020) Franck Morschhauser et al. LEUKEMIA
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
- (2020) F. André et al. ANNALS OF ONCOLOGY
- Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology
- (2019) Giuseppe Curigliano et al. DRUG SAFETY
- Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer
- (2019) Angela Esposito et al. JAMA Oncology
- Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
- (2019) Loretta J Nastoupil et al. Lancet Haematology
- Critical roles for the phosphatidylinositide 3-kinase isoforms p110β and p110γ in thrombopoietin-mediated priming of platelet function
- (2019) Samantha F. Moore et al. Scientific Reports
- Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
- (2019) Ariella B. Hanker et al. Cancer Discovery
- PIK3CA in cancer: The past 30 years
- (2019) Rand Arafeh et al. SEMINARS IN CANCER BIOLOGY
- DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma
- (2019) Ian W. Flinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial
- (2019) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting PI3K signaling in cancer: Challenges and advances
- (2019) Maria Chiara De Santis et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS
- (2019) Angela Molinaro et al. Cell Metabolism
- P110β in the ventromedial hypothalamus regulates glucose and energy metabolism
- (2019) Teppei Fujikawa et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2
- (2019) Lei Zhou et al. NATURE
- PI3K isoforms in cell signalling and vesicle trafficking
- (2019) Benoit Bilanges et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alpelisib: First Global Approval
- (2019) Anthony Markham DRUGS
- Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
- (2019) Jeff P. Sharman et al. JOURNAL OF CLINICAL ONCOLOGY
- p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity
- (2019) Carolina Torres et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Enhanced β-adrenergic signalling underlies an age-dependent beneficial metabolic effect of PI3K p110α inactivation in adipose tissue
- (2019) Caroline Araiz et al. Nature Communications
- The use of buparlisib as a radiosentisiser: What about toxicity?
- (2019) Peter A. van Dam EUROPEAN JOURNAL OF CANCER
- Inhibiting PI3 kinase-γ in both myeloid and plasma cells remodels the suppressive tumor microenvironment in desmoplastic tumors
- (2019) Xueqiong Zhang et al. JOURNAL OF CONTROLLED RELEASE
- Human amniotic mesenchymal stem cells and their paracrine factors promote wound healing by inhibiting heat stress-induced skin cell apoptosis and enhancing their proliferation through activating PI3K/AKT signaling pathway
- (2019) Jing-Yuan Li et al. Stem Cell Research & Therapy
- Function, Regulation and Biological Roles of PI3Kγ Variants
- (2019) Nürnberg et al. Biomolecules
- Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia
- (2019) Ian W. Flinn et al. AMERICAN JOURNAL OF HEMATOLOGY
- Management of toxicity to isoform α-specific PI3K inhibitors
- (2019) S E Nunnery et al. ANNALS OF ONCOLOGY
- Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study
- (2019) Martin Dreyling et al. AMERICAN JOURNAL OF HEMATOLOGY
- PI3K/AKT/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis
- (2018) Pallavi Varshney et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Phosphoinositide 3-Kinase Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth
- (2018) Mingchuan Li et al. CIRCULATION
- Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition
- (2018) A. K. Dewan et al. CLINICAL AND EXPERIMENTAL DERMATOLOGY
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Angelo Di Leo et al. LANCET ONCOLOGY
- Targeting the PI3K pathway in cancer: are we making headway?
- (2018) Filip Janku et al. Nature Reviews Clinical Oncology
- Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages
- (2018) Evangelia Goulielmaki et al. Cell Death & Disease
- Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
- (2018) Antonio Cuneo et al. HEMATOLOGICAL ONCOLOGY
- Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
- (2018) Benjamin D. Hopkins et al. NATURE
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas
- (2018) Bruce D. Cheson et al. Clinical Lymphoma Myeloma & Leukemia
- Duvelisib: First Global Approval
- (2018) Hannah A. Blair DRUGS
- The Isoform Selective Roles of PI3Ks in Dendritic Cell Biology and Function
- (2018) Ezra Aksoy et al. Frontiers in Immunology
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
- (2018) Dejan Juric et al. JAMA Oncology
- PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma
- (2017) Benjamin L. Lampson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
- (2017) Martin Dreyling et al. JOURNAL OF CLINICAL ONCOLOGY
- A slowly developed severe cutaneous adverse reaction to idelalisib
- (2017) L. Huilaja et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) José Baselga et al. LANCET ONCOLOGY
- Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Denis Soulières et al. LANCET ONCOLOGY
- PIK3CB/p110β is a selective survival factor for glioblastoma
- (2017) Kevin J Pridham et al. NEURO-ONCOLOGY
- Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
- (2017) Xiaohong Zhao et al. Nature Communications
- CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells
- (2017) Jing Zhang et al. Cell Reports
- Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
- (2016) P. M. Barr et al. BLOOD
- Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
- (2016) B. L. Lampson et al. BLOOD
- Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110
- (2016) Y. Nakanishi et al. CANCER RESEARCH
- Idelalisib-related pneumonitis
- (2016) Eglantine Haustraete et al. EUROPEAN RESPIRATORY JOURNAL
- PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition
- (2016) Hua-Fu Zhao et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management
- (2016) Jonathan W. Goldman et al. ONCOLOGIST
- Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
- (2016) Jacqueline C. Barrientos OncoTargets and Therapy
- Idelalisib-associated Enterocolitis
- (2015) Christine Y. Louie et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Idelalisib-associated Colitis
- (2015) Anna-Sophie Weidner et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Class IA Phosphatidylinositol 3-Kinase Isoform p110 Mediates Vascular Remodeling
- (2015) M. Vantler et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
- (2015) Sarit Schwartz et al. CANCER CELL
- Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
- (2015) Q. Yang et al. CLINICAL CANCER RESEARCH
- High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models
- (2015) Rute B. Marques et al. EUROPEAN UROLOGY
- Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers
- (2015) Bernard Barlaam et al. JOURNAL OF MEDICINAL CHEMISTRY
- Management of adverse events associated with idelalisib treatment: expert panel opinion
- (2015) Steven E. Coutré et al. LEUKEMIA & LYMPHOMA
- Idelalisib: First Global Approval
- (2014) Anthony Markham DRUGS
- Inhibition of PI3K Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel
- (2014) U. Hancox et al. MOLECULAR CANCER THERAPEUTICS
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma
- (2012) L. Albiges et al. ANNALS OF ONCOLOGY
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110δ
- (2010) Jennifer K. Uno et al. GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started